Axsome Therapeutics Enters $570MM Term Loan and Revolving Credit Facility with Blackstone
NEW YORK – May 13, 2025 – Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that it has entered into a $570 million term loan...
Read moreDetails










